Inscription Capital LLC lessened its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 6.3% through the third quarter, in keeping with its most up-to-date disclosure with the Securities and Change Fee (SEC). The fund owned 22,210 shares of the corporate’s inventory after promoting 1,503 shares through the interval. Inscription Capital LLC’s holdings in Johnson & Johnson had been value $3,599,000 as of its most up-to-date submitting with the Securities and Change Fee (SEC).
A number of different hedge funds have additionally modified their holdings of JNJ. Innealta Capital LLC bought a brand new place in shares of Johnson & Johnson within the 2nd quarter value roughly $27,000. Mowery & Schoenfeld Wealth Administration LLC grew its place in shares of Johnson & Johnson by 58.7% within the third quarter. Mowery & Schoenfeld Wealth Administration LLC now owns 246 shares of the corporate’s inventory value $40,000 after shopping for a further 91 shares over the past quarter. MFA Wealth Advisors LLC bought a brand new place in shares of Johnson & Johnson within the 2nd quarter value roughly $43,000. Fairfield Monetary Advisors LTD bought a brand new place in shares of Johnson & Johnson within the 2nd quarter value roughly $46,000. Lastly, Fairway Wealth LLC grew its place in shares of Johnson & Johnson by 217.1% within the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the corporate’s inventory value $49,000 after shopping for a further 228 shares over the past quarter. 69.55% of the inventory is owned by hedge funds and different institutional traders.
Johnson & Johnson Inventory Efficiency
Shares of NYSE JNJ opened at $160.14 on Wednesday. The corporate has a present ratio of 1.07, a fast ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $143.13 and a 12 month excessive of $168.85. The corporate has a 50 day easy shifting common of $163.45 and a two-hundred day easy shifting common of $155.28. The inventory has a market cap of $385.41 billion, a price-to-earnings ratio of 9.98, a PEG ratio of two.90 and a beta of 0.52.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final introduced its quarterly earnings information on Tuesday, October fifteenth. The corporate reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a web margin of 19.14% and a return on fairness of 35.46%. The enterprise had income of $22.47 billion through the quarter, in comparison with analysts’ expectations of $22.17 billion. Throughout the identical interval within the earlier yr, the enterprise posted $2.66 EPS. The enterprise’s quarterly income was up 5.2% in comparison with the identical quarter final yr. As a bunch, analysts predict that Johnson & Johnson will submit 9.94 earnings per share for the present yr.
Johnson & Johnson Publicizes Dividend
The corporate additionally not too long ago introduced a quarterly dividend, which will probably be paid on Tuesday, December tenth. Buyers of file on Tuesday, November twenty sixth will probably be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of three.10%. The ex-dividend date of this dividend is Tuesday, November twenty sixth. Johnson & Johnson’s dividend payout ratio is presently 30.92%.
Insider Exercise at Johnson & Johnson
In associated information, VP Robert J. Decker bought 5,635 shares of the enterprise’s inventory in a transaction on Friday, August thirtieth. The shares had been bought at a median worth of $165.06, for a complete worth of $930,113.10. Following the completion of the transaction, the vice chairman now straight owns 18,973 shares within the firm, valued at $3,131,683.38. The commerce was a 0.00 % lower of their place. The transaction was disclosed in a doc filed with the SEC, which is on the market at the SEC web site. Firm insiders personal 0.16% of the corporate’s inventory.
Analyst Upgrades and Downgrades
Plenty of analysis analysts have not too long ago issued reviews on the inventory. TD Cowen lower their worth goal on shares of Johnson & Johnson from $195.00 to $185.00 and set a “purchase” score on the inventory in a analysis report on Thursday, July 18th. Wells Fargo & Firm lifted their worth goal on shares of Johnson & Johnson from $163.00 to $166.00 and gave the inventory an “equal weight” score in a analysis report on Wednesday, October sixteenth. Cantor Fitzgerald reiterated an “chubby” score and issued a $215.00 goal worth on shares of Johnson & Johnson in a analysis be aware on Wednesday, October sixteenth. Daiwa Capital Markets lower shares of Johnson & Johnson from an “outperform” score to a “impartial” score and lowered their goal worth for the inventory from $160.00 to $150.00 in a analysis be aware on Tuesday, July twenty third. Lastly, Morgan Stanley lifted their goal worth on shares of Johnson & Johnson from $169.00 to $175.00 and gave the inventory an “equal weight” score in a analysis be aware on Wednesday, October sixteenth. Six funding analysts have rated the inventory with a maintain score, seven have issued a purchase score and one has given a powerful purchase score to the inventory. Primarily based on information from MarketBeat, the inventory presently has a median score of “Reasonable Purchase” and a median worth goal of $175.93.
Learn Our Newest Report on Johnson & Johnson
Johnson & Johnson Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare discipline worldwide. The corporate’s Progressive Drugs phase presents merchandise for numerous therapeutic areas, akin to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious ailments comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, akin to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by means of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Learn Extra
Obtain Information & Rankings for Johnson & Johnson Every day – Enter your electronic mail deal with beneath to obtain a concise day by day abstract of the most recent information and analysts’ scores for Johnson & Johnson and associated firms with MarketBeat.com’s FREE day by day electronic mail publication.
